A recent study conducted in China examined the impact of pre-existing lung diseases on the outcomes of COVID-19 in cancer patients who had received immune checkpoint inhibitors (ICIs). The study found that lung diseases, specifically interstitial lung disease (ILD) and atelectasis, were associated with worse clinical outcomes, severe symptoms, and increased respiratory support in these patients. However, lung cancer, pneumonia, and chronic bronchitis/COPD were not found to be associated with COVID-19 outcomes. The study emphasizes the importance of considering pre-existing lung diseases in the prevention and treatment of COVID-19, particularly in high-risk patients with poor prognoses. Further research is needed to better understand the underlying mechanisms. [Extracted from the article]